Sclerostin antibody improves alveolar bone quality in the Hyp mouse model of X-linked hypophosphatemia (XLH)
Abstract X-linked hypophosphatemia (XLH) is a rare disease of elevated fibroblast growth factor 23 (FGF23) production that leads to hypophosphatemia and impaired mineralization of bone and teeth. The clinical manifestations of XLH include a high prevalence of dental abscesses and periodontal disease...
Main Authors: | Kelsey A. Carpenter, Delia O. Alkhatib, Bryan A. Dulion, Elizabeth Guirado, Shreya Patel, Yinghua Chen, Anne George, Ryan D. Ross |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Publishing Group
2023-10-01
|
Series: | International Journal of Oral Science |
Online Access: | https://doi.org/10.1038/s41368-023-00252-1 |
Similar Items
-
Impaired 1,25 dihydroxyvitamin D3 action and hypophosphatemia underlie the altered lacuno-canalicular remodeling observed in the Hyp mouse model of XLH.
by: Ye Yuan, et al.
Published: (2021-01-01) -
X-linked hypophosphatemia (XLH): Mutations compromising PHEX structure reflect a severe phenotype
by: Whyte, M, et al.
Published: (1999) -
Kbus/Idr, a mutant mouse strain with skeletal abnormalities and hypophosphatemia: Identification as an allele of 'Hyp'
by: Kimura Atsushi, et al.
Published: (2011-08-01) -
Impaired 1,25-dihydroxyvitamin D3 action underlies enthesopathy development in the Hyp mouse model of X-linked hypophosphatemia
by: Rakshya Rana, et al.
Published: (2023-09-01) -
Dental health of pediatric patients with X-linked hypophosphatemia (XLH) after three years of burosumab therapy
by: Rafi Brener, et al.
Published: (2022-08-01)